MedTrace Logo

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

NCT03620474 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-10-10

No results posted yet for this study

Summary

To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.

Conditions

Interventions

DRUG

PRI-724

twice a week for 4 hours continuous intravenous administration of PRI-724

Sponsors & Collaborators

  • Prism Pharma Co., Ltd.

    collaborator INDUSTRY

  • Kyushu University

    collaborator OTHER

  • National Center for Global Health and Medicine, Japan

    collaborator OTHER_GOV

  • Japan Agency for Medical Research and Development

    collaborator OTHER_GOV

  • Ohara Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Kiminori Kimura, MD

    lead OTHER

Principal Investigators

  • Kiminori Kimura, MD · Komagome Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-24
Primary Completion
2021-07-13
Completion
2022-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620474 on ClinicalTrials.gov